TrialAntimicrobial agents and chemotherapy2021

Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.

Maria E Cilento et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.